Impact of non-weight-dependent low-dose somatropin on bone accrual in childhood-onset GH deficient in the transition: an 18-month randomized controlled trial.

ABSTRACT:

Objective

Discontinuation of growth hormone therapy (rhGH) upon completion of linear growth may adversely affect bone mineral density and content (BMD/BMC) in adolescents with childhood-onset GH deficiency (CO-GHD) and predisposition to osteoporosis. Although the benefits of weight-dependent somatropin high doses over bone gain are established, little is known about fixed low doses. We analyzed the impact of non-weight-based low-dose somatropin on bone accrual during the transition among CO-DGH patients, treated since childhood.

Methods

Lumbar spine (LS) and whole-body (WB) BMD and BMC were measured at baseline and after 18 months in 54 adolescents (age: 16.8 ± 1.6 years). They were retested and reclassified as GH sufficient (GHS, n = 28) and GH insufficient. The last group

SUBMITTER: Kuba VM 

PROVIDER: S-EPMC11889693 | biostudies-literature | 2025 Mar-Apr

REPOSITORIES: biostudies-literature